¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26
±³À°ÀÏÀÚ : 2021-08-26
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : À±ÁöÇö
¿¬¶ôó : 070-4895-6129  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-26 CH A 09:30~10:00 NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML  Michael Heuser(MHH Hospital) 
±³À°½Ã°£ 08-26 CH A 10:00~10:30 Conditioning Intensity of Allogeneic Transplantation for AML with MRD  Christopher S. Hourigan(NIH) 
±³À°½Ã°£ 08-26 CH A 10:40~11:10 Engineering and Design for Next Generation CAR-T Cells  Sham Mailankody(MSKCC) 
±³À°½Ã°£ 08-26 CH A 11:20~11:50 Machine Learning Research for Hematopoietic Stem Cell Transplantation  Yasuyuki Arai(Kyoto University) 
±³À°½Ã°£ 08-26 CH A 11:50~12:20 Current Statistical Issues in Hematopoietic Cell Transplantation  Haesook T. Kim(Dana-Farber Cancer Institute) 
±³À°½Ã°£ 08-26 CH B 12:40~13:20 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Thomas Martin(University of California San Francisco) 
±³À°½Ã°£ 08-26 CH A 13:30~14:30 Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants  Eun Sang Yi(Korea University Guro Hospital) 
±³À°½Ã°£ 08-26 CH A 14:40~15:10 High Throughput Single Cell Analysis in AML  Koichi Takahashi(MDACC) 
±³À°½Ã°£ 08-26 CH A 15:10~15:40 Therapeutic Implications in AML using Prospective Genomic Profiling  Omar Abdel-Wahab(MSKCC) 
±³À°½Ã°£ 08-26 CH A 15:40~16:10 Clonal Hematopiesis of Indeterminate Potential in Transplantation  Kyoung Ha Kim(Soonchunhyang University Hospital) 
±³À°½Ã°£ 08-26 CH A 16:30~17:00 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML  Richard T. Maziarz(Oregon Health and Science University) 
±³À°½Ã°£ 08-26 CH A 17:00~17:30 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS  Tapan Kadia(MDACC) 
±³À°½Ã°£ 08-26 CH A 17:30~18:00 Treatment Strategies after Allogeneic HSCT in Relapsed ALL  Ik-Chan Song(Chungnam National University College of Medicine) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 27ÀÏ (2ÀÏÂ÷) : 2021-08-27
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦19ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2021-08-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
525 ¼­¿ï ´ëÇѼҾƽŰæÇÐȸ µÎÅ뿬±¸È¸ ÇмúÁý´ãȸ : 2018-09-14 0 828 2018-08-22
524 ÀüºÏ ´ëÇÑÀÇ»çÇùȸ 2018 Àü¶óºÏµµ °øÁߺ¸°ÇÀÇ»ç Á÷¹«±³À° (2Â÷) : 2018-09-14 0 1,713 2018-08-22
523 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-14 0 779 2018-08-22
522 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Practical Disaster Preparedness - from Evidence to Practice : 2018-09-13 0 886 2018-08-22
521 ÀüºÏ 2018 Àü¶óºÏµµ °øÁߺ¸°ÇÀÇ»ç Á÷¹«±³À° (1Â÷) : 2018-09-13 0 1,117 2018-08-22
520 °æ±â °í·Á´ëÇб³ ¾È»êº´¿ø ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ Á¦77Â÷ ¿ù·ÊÁý´ãȸ : 2018-09-13 0 1,010 2018-08-22
519 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-13 0 496 2018-08-22
518 ºÎ»ê ´ëÇÑ°ñ´ë»çÇÐȸ 2018³â ºÎ»ê,¿ï»ê,°æ³²Áöȸ Á¦2Â÷ Áý´ãȸ : 2018-09-12 0 714 2018-08-22
517 ±¤ÁÖ Á¶¼±´ëº´¿ø Á¦ 157Â÷ ´ëÇÑÇǺΰúÇÐȸ È£³²Áöȸ : 2018-09-12 0 814 2018-08-22
516 ÀÎõ ÀÎõ¼º¸ðº´¿ø ´ëÇÑÇǺΰúÇÐȸ Á¦39Â÷ ÀÎõÁöºÎȸ ÇмúÁý´ãȸ : 2018-09-12 0 2,777 2018-08-22
515 ÀÎõ ±æº´¿ø Çѱ¹¿©ÀÚÀÇ»çȸ ºñŸ¹ÎDÀÇ ÀÌÇØ¿Í ÀÓ»óÀû¿ë : 2018-09-12 0 1,436 2018-08-22
514 ¼­¿ï °¡Å縯´ëÇб³¿©Àǵµ¼º¸ðº´¿ø À̺ñÀÎÈÄ°ú Çù·Âº´ÀÇ¿ø °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-11 0 1,094 2018-08-22
513 °æ±â °í·Á´ë¾È»êº´¿ø ´ëÇÑÇǺΰúÇÐȸ Á¦ 60Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2018-09-11 0 1,781 2018-08-22
512 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Æó¼¾ÅÍ °³¿øÀÇ °­Á : 2018-09-11 0 808 2018-08-22
511 ¼­¿ï ÀÎÁ¦ÀÇ´ë ¼­¿ï¹éº´¿ø Á¦262ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ½ÉÆ÷Áö¾ö °³ÃÖ : 2018-09-10 0 742 2018-08-22
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷